Nexalin Technology Names Carmi Masha Technologies Ltd. as Sole Distributor for Israel
Exclusive Distribution Agreement: Nexalin Technology has signed an exclusive distribution agreement with Carmi Masha Technologies to market its Gen-2 Console ("SYNC") neurostimulation device in Israel, following regulatory approval for its use in treating mental health disorders.
Focus on Mental Health Treatment: The SYNC device is designed to provide non-invasive, drug-free treatment for conditions such as insomnia, depression, and anxiety, with potential future applications for PTSD, TBI, and dementia.
Partnership Goals: The collaboration aims to leverage Carmi Masha's expertise in introducing medical technologies to enhance access to Nexalin's innovative solutions in Israel, aligning with the growing demand for effective mental health treatments.
Global Expansion Strategy: This agreement is part of Nexalin's broader strategy to expand its presence in international markets, particularly in the Middle East, while continuing to develop advanced neurostimulation products for mental health issues.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on NXL
About NXL
About the author

Nexalin Technology (NXL) Receives Nasdaq Compliance Notification, 180 Days to Regain Minimum Bid Price
- Compliance Notification: Nexalin Technology received a Nasdaq notification on January 21, 2026, indicating non-compliance with the $1 minimum bid price requirement, which could negatively impact investor confidence and market performance.
- Compliance Period: The company has been granted a 180-day compliance period until July 20, 2026, to regain compliance, and failure to meet this requirement may lead to more severe market consequences.
- Operational Evaluation: Nexalin is evaluating operational and financial measures to improve its share price performance, indicating the company's commitment to restoring its stock price and potentially adopting various strategies to enhance market confidence.
- No Reverse Split Consideration: The company is currently not considering a reverse stock split, reflecting management's confidence in the existing capital structure while also indicating a cautious approach to market conditions.

Nexalin Technology Receives Nasdaq Warning for Non-Compliance with Minimum Bid Price
- Nasdaq Warning: Nexalin Technology received a notification on January 21, 2026, from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share, posing a risk to its continued listing on the exchange.
- Compliance Deadline: The company has been granted 180 days until July 20, 2026, to regain compliance; failure to do so may lead to delisting, which could negatively impact investor confidence and market perception.
- Price Monitoring Measures: In response to the declining stock price, Nexalin intends to continuously monitor its bid price and is considering various strategies to improve its financial position, aiming to mitigate short-term adverse effects on its trading price.
- Product Market Outlook: Nexalin's neurostimulation devices have been approved in China, Brazil, Oman, and Israel, and despite facing stock price pressures, the company remains committed to addressing the global mental health crisis through innovative technology, maintaining its competitive edge in the market.









